GlassScriptPhysician profile
Johnathan David Goodwin
NPI 1295963379
$5,050.97
in general payments reported to CMS, 2019-2025
23 companies · $763 in 2025
The $763 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $432 · 2020: $400 · 2021: $876 · 2022: $734 · 2023: $883 · 2024: $963 · 2025: $763.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,336 · Gift: $245 · Education: $27.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,336.09 |
| Gift | $245.43 |
| Education | $27.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,066.20 | 2019-2025 | |
| Braintree Laboratories, INC. | $775.99 | 2019-2024 | Suflave, Sutab |
| Janssen Biotech, INC. | $518.94 | 2019-2025 | Stelara, Tremfya, Remicade |
| Pfizer INC. | $327.51 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $245.48 | 2019-2025 | Entyvio, Eohilia |
| Janssen Scientific Affairs, LLC | $218.41 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $194.70 | 2022-2025 | Dupixent |
| Merck Sharp & Dohme LLC | $123.77 | 2021-2024 | Dificid |
| Aimmune Therapeutics, INC. | $101.68 | 2024-2025 | Vowst, Zenpep |
| Genzyme Corporation | $101.35 | 2024-2025 | |
| Gilead Sciences, INC. | $70.56 | 2022-2023 | |
| Medtronic, INC. | $45.77 | 2025 | Interstim |
| Redhill Biopharma INC. | $40.81 | 2021 | |
| Lilly USA, LLC | $37.56 | 2024-2025 | Omvoh |
| Allergan, INC. | $34.72 | 2019-2020 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evoke Pharma, INC. | $33.58 | 2025 | |
| Intercept Pharmaceuticals, INC. | $27.52 | 2021-2023 | Ocaliva |
| Phathom Pharmaceuticals, INC. | $23.99 | 2025 | Voquezna |
| Ipsen Biopharmaceuticals, INC | $21.36 | 2025 | Iqirvo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.30 | 2019 | |
| Ardelyx, INC. | $13.54 | 2024 | Ibsrela |
| Ferring Pharmaceuticals INC. | $13.23 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Johnathan Goodwin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.